STA Pharmaceutical Co., Ltd., (WuXi
STA)--a subsidiary of WuXi
AppTec--announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the U.S.
SHANGHAI, June 29, 2019 -- WuXi
AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019.
Biologies plans to expand its new integrated biologics conjugation solution center to include commercial manufacturing in Wuxi
Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has signed a strategic partnership letter of intent with a global vaccine leader, it was reported yesterday.
Biologics company WuXi
Biologics said on Monday that WuXi
Vaccines has entered into a Letter of Intent (LOI) for a strategic 20-year,USD3bn manufacturing and supply partnership with a global vaccine company.
7 May 2019 - China-based pharmaceutical and medical device company WuXi
AppTec has acquired California, US-based clinical research services provider Pharmapace, Inc., the company said.
Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
NetApp has partnered with WuXi
NextCODE are working to improve health for people around the globe.
Securities and Exchange Commission, affirmed China-based Wuxi
Construction and Development Investment Co., Ltd.'s (WCDI) Long-Term Foreign- and Local-Currency Issuer Default Ratings (IDRs) at 'BBB+'.
Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Immune Pharmaceuticals (Nasdaq: IMNP) ('Immune'), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced a development and manufacturing agreement for the production of bertilimumab, Immune's first-in-class anti-eotaxin-1 monoclonal antibody, Monday (7/9).
Biologics has selected 4,000 liter (L) Custom Single Run (CSR) disposable bioreactors from ABEC for its new commercial manufacturing facility (MFG4) in Wuxi
city, Jiangsu, China.